Immunotherapy of melanoma

被引：43

作者：

Parmiani, G ^{[1
]}

Castelli, C ^{[1
]}

Rivoltini, L ^{[1
]}

Casati, C ^{[1
]}

Tully, GA ^{[1
]}

Novellino, L ^{[1
]}

Patuzzo, A ^{[1
]}

Tosi, D ^{[1
]}

Anichini, A ^{[1
]}

Santinami, M ^{[1
]}

机构：

[1] Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy

来源：

SEMINARS IN CANCER BIOLOGY | 2003年 / 13卷 / 06期

关键词：

melanoma; antigens; vaccination; adoptive immunotherapy; TUMOR-INFILTRATING LYMPHOCYTES; COLONY-STIMULATING FACTOR; CD8(+) T-CELLS; PHASE-I TRIAL; HEAT-SHOCK-PROTEIN-70 PEPTIDE COMPLEXES; INCOMPLETE FREUNDS-ADJUVANT; BLOOD MONONUCLEAR-CELLS; PULSED DENDRITIC CELLS; HEAT-SHOCK PROTEINS; METASTATIC MELANOMA;

D O I：

10.1016/j.semcancer.2003.09.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The rationale for immunotherapy of human melanoma is based on the knowledge acquired in the molecular characterization of T cell defined antigens which are recognized in vitro by patients' lymphocytes. Based on this information, active immunotherapy (vaccination) and adoptive immunotherapy trials were conducted in metastatic melanoma patients. This review highlights the most important clinical studies and discuss their limits, in terms of both immune and clinical response considering the formulation of the vaccine (cellular, peptide/protein; DNA, etc.) or the features of immune cells used in adoptive immunotherapy. This new knowledge, along with that of escape mechanisms, should allow to improve significantly the clinical response rate in the immunotherapy of melanoma. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：391 / 400

页数：10

共 79 条

[1] Malignant effusions and immunogenic tumour-derived exosomes
Andre, F
Schartz, NEC
Movassagh, M
Flament, C
Pautier, P
Morice, P
Pomel, C
Lhomme, C
Escudier, B
Le Chevalier, T
Tursz, T
Amigorena, S
Raposo, G
Angevin, E
Zitvogel, L
[J]. LANCET, 2002, 360 (9329) : 295 - 305
[2] Banchereau J, 2001, CANCER RES, V61, P6451
[3] High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene
Baurain, JF
Colau, D
van Baren, N
Landry, C
Martelange, V
Vikkula, M
Boon, T
Coulie, PG
[J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (11) : 6057 - 6066
[4] Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings
Belli, F
Testori, A
Rivoltini, L
Maio, M
Andreola, G
Sertoli, MR
Gallino, G
Piris, A
Cattelan, A
Lazzari, I
Carrabba, M
Scita, G
Santantonio, C
Pilla, L
Tragni, G
Lombardo, C
Arienti, F
Marchianò, A
Queirolo, P
Bertolini, F
Cova, A
Lamaj, E
Ascani, L
Camerini, R
Corsi, M
Cascinelli, N
Lewis, JJ
Srivastava, P
Parmiani, G
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4169 - 4180
[5] M-Vax: an autologous, hapten-modified vaccine for human cancer
Berd, D
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (03) : 335 - 342
[6] Anti-idiotype vaccine against cancer
Bhattacharya-Chatterjee, M
Chatterjee, SK
Foon, KA
[J]. IMMUNOLOGY LETTERS, 2000, 74 (01) : 51 - 58
[7] BOS JL, 1989, CANCER RES, V49, P4682
[8] Castelli C, 2001, CANCER RES, V61, P222
[9] Chang AE, 2002, CLIN CANCER RES, V8, P1021
[10] Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO

← 1 2 3 4 5 6 7 8 →